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INTRODUCTION 
Food allergy is described as “an adverse health effect that aris-
es from a specific response that occurs reproducibly on expo-
sure to a given food.” In contrast, food intolerance is a non-im-
mune reaction that includes toxic, pharmacologic, metabolic, 
and undefined mechanisms.1 It is estimated that food allergy 
affects an average of 4% to 8% of children and 5% of adults 
worldwide.2 A detailed meta-analysis of 51 self-reported allergy 
studies to milk, egg, peanut, and seafood, revealed that the inci-
dence of food allergy ranges from 3% to 35%. In another meta-
analysis, which included 36-population-based studies of aller-
gy to vegetables and fruits, 0.1% to 4.3% of individuals were al-
lergic to fruits and tree nuts, less than 1% for wheat, soy, and 
sesame and from 0.1% to 1.4% for vegetables.3 Childhood aller-
gies typically resolve by 3 years of age; however, only 11% of al-
lergies to egg and 19% of allergies to milk resolve by the age of 4 
years with about 80% of the above-mentioned food allergies re-
solving by the 16 years of age.4 Allergies to shellfish, fish, tree 
nuts, and peanut can be persistent, while childhood allergies to 
soy, wheat, egg, and milk usually resolve during childhood. It is 
worth to underline that the incidence of food allergies seems to 
be increasing over the last 2 decades. Data from the US Centers 
for Disease Control and Prevention concluded that prevalence 
of food allergies increased by 1.7% over the last 20 years. Sur-
prisingly, there is no approved treatment for food allergies, oth-
er than allergen avoidance and emergency treatment in cases 
of accidental ingestion. As can be imagined, the patient’s quali-
ty of life is affected because of anxiety and fear of unintentional 
ingestion.5,6 The need for new therapeutic approaches to elimi-
nate or reduce the severity of allergic reactions upon ingestion 
is driving new studies that investigate the mechanisms of oral 
tolerance. One promising area of current investigation is the 
use of oral and sublingual allergen immunotherapy for treat-
ment of food allergies.7  
Allergy development
Understanding the mechanisms of allergic diseases may help 
unravel mechanisms that promote tolerance rather than de-
sensitization in food allergy. Allergy is typically considered an 
inappropriate type 2-mediated immunological response, with 
increased numbers of allergen-specific T helper type 2 lympho-
cytes (Th2) and elevated allergen-specific IgE immunoglobu-
lins.8 Th2 cells and innate type 2 lymphoid cells (ILC2) that ex-
press GATA Binding Protein 3 (GATA3) and produce interleu-
kin-4 (IL-4), IL-5, IL-13 are involved in type 2 immunity. These 
cells promote basophil, mast cell, and eosinophil activation 
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along with allergen-specific immunoglobulin E (IgE) produc-
tion. Type 2 immunity has evolved to protect against parasite 
infections. However, when dysregulated, Th2 responses con-
tribute to the development of allergic diseases that usually re-
quire 2 phases. In the first phase, allergen presentation by den-
dritic cells to naïve T cells results in the generation of Th2 cells. 
IL-4, IL-5, and IL-13 produced by newly differentiated Th2 cells 
induce immunoglobulin heavy chain class switching to IgE. 
Later, IgE produced by plasma cells binds to high-affinity IgE 
receptors on mast cells and basophils. Subsequently, when ex-
posure to the allergen occurs for the second time, the allergen 
binds to and crosslinks IgE antibodies present on the surface of 
basophils and mast cells. Activated cells release a plethora of 
inflammatory mediators, such as histamine and leukotrienes, 
which contribute to symptoms associated with allergic inflam-
mation. In the skin, symptoms manifest as swelling, erythema, 
and pruritus, while reduced lung function, airway hypersensi-
tivity and remodeling are associated with respiratory allergies.8
Besides Th2 cells, newly described CD4+ T-helper subsets, in-
cluding Th9, Th17, and Th22, may play a role in allergic diseas-
es. Initially, IL-9 was described as a Th2 cell-derived cytokine. 
Later, a separate Th9 subset of cells was defined. Th9 cells dif-
ferentiate in the presence of transforming growth factor beta 
(TGF-β) and IL-4. In the ovalbumin (OVA)-induced model of 
airway inflammation, IL-9 neutralization strongly reduces aller-
gic symptoms,9 and the transfer of OVA-specific Th9 cells into T-
cell deficient mice promotes asthma symptoms. In humans, in-
creased numbers of Th9 cells have been shown in the blood of 
allergic patients.10 In summary, protective and inflammatory 
roles of Th9 cells in mouse models and humans have been de-
scribed. 
As soon as naïve T cells are activated by IL-6, TGF-β, and IL-
23, their differentiation is polarized into Th17 cells. Polarizing 
cytokines activate the transcription factor STAT3, which further 
induces the RAR-related orphan steroid receptor (RORγt), a key 
transcriptional regulator of Th17 cells. Th17 cells produce the 
main cytokines IL-17A and IL-17F. Furthermore, Th17 cells 
may produce IL-22 that is responsible for epithelial cell homeo-
stasis and antimicrobial defense, along with tumor necrosis 
factor alpha (TNFα) and granulocyte-monocyte colony-stimu-
lating factor (GM-CSF) that recruit and activate neutrophils.11 
Expansion of Th17 cells is supported by IL-23, and Th17 cells 
are notably abundant in gut mucosal tissues. The main func-
tion of Th17 cells is the induction and coordination of neutro-
phil responses to ingest and kill extracellular microbes. Howev-
er, psoriasis, inflammatory bowel disease, rheumatoid arthritis, 
and multiple sclerosis are associated with  inappropriate Th17 
cell responses.11 
Another subset of T-helper cells that are closely related to 
Th17 cells is Th22 cells. The main cytokine produced by Th22 
cells is IL-22. Because of the preferential expression of IL-22 re-
ceptor 1 (IL-22R1) on cells of epithelial origin, IL-22 is a unique 
cytokine produced by immune-cells and acts only on tissue 
cells.12 The first immune mediated disorder that has been asso-
ciated with IL-22 is psoriasis. IL-22 expression is up-regulated 
in the lesional skin as compared to the non-lesional psoriatic 
and healthy skin.12 The anti-psoriatic therapy significantly de-
creases IL-22 expression in the lesional skin. Moreover, IL-22 
levels are also elevated in the inflamed skin of atopic dermatitis 
(AD) patients.12 In the gastrointestinal track, the role of IL-22 
has been mainly investigated in inflammatory bowel disease, in 
which IL-22 is considered to play a protective role by acting on 
intestinal epithelial cells and inducing the production of anti-
microbial peptides that modulate the colonic microbiota, ex-
pression of mucus-associated molecules, and reconstitution of 
the mucus-producing goblet cells, as well as epithelial cell pro-
liferation that contributes to the regeneration and repair of epi-
thelial layers.13 Interestingly, increased levels of IL-22 mRNA 
and protein have been reported in the blood of asthmatic pa-
tients and in murine asthma models.14 IL-22 has a dual role in 
asthma-associated lung inflammation. Depending on the route 
and time of administration, IL-22 may reduce or exacerbate 
lung pathology and inflammation. Taking into account that 
Th22 cells seem to play a role in allergic diseases, it would be 
interesting to investigate the role of Th22 cells in food allergy.
Another cell type that influences responses during allergic in-
flammation is epithelial cells. Intestinal epithelial cells form a 
tight and selective barrier that allow highly controlled, paracel-
lular, and transcellular transport of molecules or antigens, and 
are necessary for the induction of appropriate immune re-
sponses in the gut. Additionally, it has been described that via 
production of thymic stromal lymphopoietin (TSLP), IL-25, 
and IL-33, epithelial cells may enhance type 2 immune re-
sponses. For example, TSLP not only modifies dendritic cells 
(DC) to preferably induce Th2-antigen-specific lymphocytes 
but also enhances basophil hematopoiesis. Epithelial cell se-
cretion of IL-25 enhances the differentiation of mast cells and 
basophils, and is associated with allergen sensitization in hu-
mans with asthma.15 Finally, epithelial-derived IL-33 has been 
shown to be essential for peanut sensitization in the mouse and 
may increase permeability of mucosal tissues.16 In addition to 
the effects on Th2 cells, TSLP, IL-25, and IL-33 induce activation 
and IL-4, IL-13, and IL-5 production from the recently discov-
ered type 2 ILCs .17
Immune response in the gut
Induction of tolerance to food allergens takes place in the gut 
and gut-associated lymphoid tissue (GALT), where the highest 
fraction of immune system cells inside the body resides. Mes-
enteric lymph nodes (MLN) and Peyer’s patches (PP) are the 
main components of the organized GALT. Payer’s patches are 
lymphoid-cell accumulation areas found in the submucosa, 
primarily the small intestine, and consist of B-cell follicles and 
surrounding T-cell areas. Immediately above the B-cell follicles 
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and below the follicle-associated epithelium, a region known 
as the subepithelial dome is present. This dome is covered by 
single layer of columnar-follicle-associated epithelium that 
separates it from the intestinal lumen. These epithelial cells 
produce lower levels of digestive enzymes, possess less pro-
nounced brush borders, and are called “microfold (M) cells.” 
The second compartment, MLN, are largest in the body and 
drain the intestine via lymphatics.18 
Below the single epithelial cell layer are multiple types of im-
mune cells, including CD4+T and CD8+T effector and regulato-
ry cells, B cells, γδ T cells, phagocytes, and antigen presenting 
cells that recognize and clear pathogens, thus contributing to 
effector mechanisms. Immune responses in the gut are effi-
ciently induced in PP and MLN. For the induction of oral toler-
ance, PP have been shown to be dispensable, while MLN are 
required.19
The initial contact between immune cells and antigens from 
the lumen is a critical step in the induction of intestinal im-
mune responses. Food proteins are processed into small pep-
tides and amino acids that in later stages will be absorbed by 
intestinal epithelial cells. This process starts in the stomach and 
continues through the duodenum and jejunum. However, im-
munologically active proteins may escape the process of diges-
tion. In the intestine, they are 3 types of cells specialized in anti-
gen uptake: M cells, intestinal epithelial cells, and dendritic 
cells (Figure). It has been recognized that M cells are only cells 
that transport antigens that come into contact with intestinal 
immune cells. Interestingly, M cells do not express major histo-
compatibility complex (MHC) class II molecules or present an-
tigens. Their role is strictly restricted to antigen transport to an-
Figure. Role of regulatory cells in the induction of oral tolerance. Food antigens are acquired by the immune system via several different mechanisms. First of all, 
dendritic cells (DC) expressing CD11b and CX3CR1 extend dendritic processes between epithelial cells and sample antigens from lumen (1). As CX3CR1+CD11b+ DC 
do not express CCR7 or migrate to mesenteric lymph node, they mainly contribute to local, antigen-specific expansion of regulatory cells. Additionally, M cells local-
ized in Payer’s patches (2), intestinal cells via paracellular (3), or transcellular route (4), and goblet cells (5) might contribute to antigen sampling. Antigens are uptak-
en by CD11C+CD103+DC. DC expressing CD11c and CD103 co-express CCR7 and migrate to MLN under homeostatic conditions. In MLN produced by  of TGF-beta, 
IL-10, RALDH, and IDO contribute to active promotion and development of Treg and Breg cells. Treg cells differentiated in MLN by CD11C+CD103+ DC up-regulate 
α4β7 integrin and CCR9 receptor that are responsible for T-cell homing from MLN to the lamina propria. In lamina propria, CD25-Foxp3--, IL-10-and TGF-β-producing 
Th3/Tr1 cells, CD25+Foxp3+ α4β7+CCR9+ iTreg cells, and IL-10+IgG4+ Breg cells suppress Th2-dependent allergic inflammation by decreasing mast cell activation, 
IL-4/IL-5/IL-13 production from ILC2 and Th2 cells, and IgE production from plasma cells. 
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tigen-presenting DC that reside below the epithelial cell layer.18 
Intestinal epithelial cells can express MHC class I and II mole-
cules, while they produce and respond to various cytokines. In 
contrast to antigen-presenting cells, enterocytes do not express 
co-stimulatory molecules that provide a second signal for full T-
cell activation and therefore may be good candidates as tolero-
genic antigen- presenting cells that contribute to the develop-
ment of oral tolerance.18 In addition, soluble, low molecular 
weight antigens can be transported from the lumen to tolero-
genic DC.20 However, well-known food allergenic molecules, 
such as lipid transfer proteins (LTP), may be transported intact 
by epithelial cells.21
Oral tolerance
Prevention and treatment of allergy, asthma, and other non-
allergic diseases, such as autoimmunity and organ transplanta-
tion, where the immune system is dysregulated may be possi-
ble if immunological tolerance can be induced.22 In general, 
immunological tolerance can develop to any substance that 
otherwise may activate the immune system. Mechanisms of 
immunological tolerance are complex and influenced by the 
following factors: antigen dose, structure, time and route of ex-
posure; genetic susceptibility, composition, and metabolic ac-
tivity of the microbiome. Administration of increasing doses of 
specific antigen in the form of allergen-specific immunothera-
py (AIT) may provide long-term curative treatment. Two main 
types of AIT, SCIT (subcutaneous immunotherapy) and SLIT 
(sublingual immunotherapy), exist when antigens are applied 
subcutaneously and sublingually, respectively. In cases of aero-
allergens and venom allergens, it has been shown that SCIT 
and SLIT induce allergen-specific Treg cells, which are critical 
to the success of AIT.23 Supporting data are accumulating for 
food allergy and other immunotherapy routes, including oral 
immunotherapy (OIT), which will be discussed in the next sec-
tion. The ultimate goal of immunotherapy is the induction of 
clinical tolerance defined as the long-term, established absence 
of allergic symptoms after allergen exposure. On the other 
hand, immunological tolerance requires suppression of aller-
gen-specific B and T cell effector responses, changes in humor-
al responses including development of IgG4 antibodies, chang-
es in the threshold dose required for activation of basophils and 
mast cells and switching from Th2 to Th1 response with ac-
companying induction of specific-Treg cells.
In food allergy, tolerance is classically described as the ab-
sence of allergic symptoms upon food intake after a period of 
food avoidance. However, in most cases, only patients remain-
ing on maintenance doses do not develop reactions and food 
desensitization rather than tolerance is accomplished. Despite 
a growing literature in the field of food allergy, it is not yet clear 
why the majority of individuals are immunologically tolerant to 
food antigens, while few individuals develop allergic sensitiza-
tion. In the present review, we focus on the mechanisms of oral 
tolerance and the role of regulatory cells in this process. In 1911, 
Wells and Osborne for the first time described a phenomenon, 
termed “oral tolerance,” by showing that guinea pigs could not 
develop anaphylaxis to proteins of corn or oats that were pres-
ent as components of their diet.24 Oral tolerance is a mecha-
nism by which potentially antigenic substances that are admin-
istered orally do not elicit cellular or humoral immune respons-
es.25 In mouse models of food allergy, mice fed with a single 
high antigen dose (50-100 mg) or with 5 times daily feeds of low 
antigen dose (0.5-1 mg) can become non-responsive to admin-
istered antigen. Low doses favor the induction of Treg cells, 
while higher doses support the anergy and deletion of antigen-
specific T cells.26 Interestingly, in the Learning Early About Pea-
nut Allergy study it has been shown that early oral introduction 
of peanuts could prevent allergy non-sensitized as well as sen-
sitized infants.27 
DC in oral tolerance
To elicit mucosal immune responses, antigen (Ag) has to be 
sampled and presented by antigen-presenting cells. Antigens 
may be acquired via several different mechanisms. First of all, 
M cells that overlie PP and goblet cells may contribute to selec-
tive sampling of viral and bacterial antigens. On the other hand, 
soluble antigens are mainly transported across epithelial cells 
by endocytosis and subsequently transported via immune cells 
to mesenteric lymph nodes.28 DC, which are professional anti-
gen-presenting cells that orchestrate immune responses by 
linking innate and adaptive immunity, may contribute to in-
duction of peripheral tolerance. Early experiments suggested 
that only immature DC contribute to generation of Treg cells 
and mature DC provide stimulation for induction of several dif-
ferent T-helper effector cell subsets. Nowadays, the current 
knowledge suggests that mature DC are also capable of induc-
ing T reg cells via different mechanisms, including cytokines 
(TGF-β, IL-10), enzymes (IDO, idoleamine 2,3-dioxygenase; 
RALHD, retinal dehydrogenase) and metabolites (RA, retinoic 
acid).29
In the gut, DC that express CD11b and CX3CR1 can extend 
dendritic processes between epithelial cells to sample antigen 
on the apical surface of epithelial cells.30 These DC, which are 
monocyte-derived cells, do not express CCR7 constitutively, do 
not migrate to MLN, and are transcriptionally more related to 
macrophages than to DC.31 However, CD11b+CX3CR1+cells ex-
press high levels of IL-10.32 Additionally, 2 additional tolerance-
associated DC have been described within the lamina propria: 
CD11c+CD103+CX3CR1- and CD11c+CD103-CX3CR1+cells.33 
In contrast to CD11b+CX3CR1+DC, CD11c+CD103+CX3CR1- 
DC constitutively express CCR7 and migrate to mesenteric 
lymph nodes under homeostatic conditions. Moreover, CD11c+ 
CD103+CX3CR1- DC do not sample antigens by extending den-
drites between tight junctions of epithelial cells, they rather sam-
ple antigens that were transported by epithelial cells, goblet 
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cells, or M cells.20,32,33 In addition to these features, CD103+ CX-
3CR1- DC express high levels of TGF-β and RALDH that is in-
volved in the production of RA from vitamin A. CD103+ CX-
3CR1- DC can also express IDO and both of these metabolic ac-
tivities contribute to active promotion and development of Treg 
cells from naïve T cells in mesenteric lymph nodes.34 Important-
ly, Treg cells differentiated with the help of CD103+CX3CR1- DC 
up-regulate, in a RA-dependent manner, α4β7 integrin, and 
CCR9 receptor that are responsible for T-cell homing from MLN 
to the lamina propria. Furthermore, CD103+ CX3CR1- DC not 
only influence T-cell responses but also direct gut-homing-IgA-
secreting plasma cells.35 The fact that different subsets of DC`s 
are present in the lamina propria may suggest that they play dis-
tinct roles in the induction of oral tolerance. It is possible that 
CD103+DC migrate to MLN where they contribute to the devel-
opment of gut-homing Treg cells. Once Treg cells are primed in 
MLN and move back to lamina propria, they interact with 
CX3CR1+DC that lack migratory capacity and can be expanded 
locally.36 
Treg cells in oral tolerance
Treg cells are potent immune regulating cells that play a cen-
tral role in controling immune responses to allergens. The main 
mechanisms underpinning Treg cell effects include production 
of inhibitory cytokines (IL-10, TGF-β and IL-35), effector cells 
cytolysis (via secretion of granzymes A and B), direct targeting 
of DC via inhibitory PD-1 (programmed cell dead protein 1) 
and CTLA4 (cytotoxic T-lymphocyte-associated protein 4)  cell 
surface molecules and metabolic disruption of effector cells 
(CD25, cAMP, adenosine, CD39, and CD73).37 Interestingly, 
Th3 cells may promote the development of induced Treg cells 
(iTregs) via TGF-β production.38 IL-10 is a key cytokine that 
controls immune response. IL-10 directly inhibits IFN-γ and 
IL-2 secretion by Th1 cells and IL-4/IL-5 production by Th2 
cells. Prolonged immune responses against antigens, which in 
several cases lead to tissue damage and inflammation, were ob-
served in IL-10-deficient mice.39 
Administration of antigens by the oral route induces 2 differ-
ent populations of Treg cells: CD4+CD25+ forkhead box P3 
(Foxp3)+ Treg cells and Th3 cells. The main mechanism of sup-
pression provided by Th3 cells is dependent on the inhibitory 
cytokine TGF-β as Th3 cells do not express Foxp3+ or CD25 but 
do express LAP (latency associated peptide) that forms a com-
plex with TGF-β. In contrast, CD4+CD25+Foxp3+ T cells, called 
iTregs, are involved in the inhibition of allergen specific Th2 
cells,40 promotion of allergen-specific IgG4 production rather 
than allergen-specific IgE41 and generation of tolerogenic DC. 
Despite the fact that specific mechanisms for oral tolerance 
maintenance by T reg cells within the lamina propria remain to 
be clarified, studies with specific deletion of Foxp3+- induced 
Treg cells proved that they are mandatory for oral tolerance.36 
Humans with mutations in the Foxp3 locus immune dysregula-
tion, polyendocrinopahty, enteropathy, X-linked [IPEX] syn-
drome)42 and Foxp3-mutant mice display failures in oral toler-
ance, which leads to inappropriate responses to many types of 
antigens, including food antigens.  Moreover, iTreg cells are es-
sential, while thymic-derived natural Treg cells which also ex-
press Foxp3 are dispensable for oral tolerance as shown by de-
letion studies in mice.43 This hypothesis is additionally support-
ed by the fact that iTreg cells rather than nTreg cells are in-
volved in the control of Th2-related mucosal inflammation.44 
Results described above suggest that Treg cells play a role in the 
constitutive suppression of responses to antigens encountered 
in GALT. Interestingly, studies in children who outgrew milk al-
lergy revealed reduced proliferation of milk-specific T effector 
cells and increased frequency of CD4+CD25+ Treg cells follow-
ing allergen challenge, suggesting that not only maintenance 
but also the development of oral tolerance requires Treg cells.45 
Oral tolerance can also be influenced by CD8+T cells and 
these cells are reduced in the lamina propria of inflammatory 
bowel disease patients compared to healthy controls.46 Howev-
er, these cells do not seem to provide tolerance against allergic 
inflammation driven by Th2 cells and are not necessary for the 
development of oral tolerance.47 
Breg cells in oral tolerance
Similarly to Treg cells, Breg cells suppress effector T cells and 
other lymphocytes via production of IL-10, IL-35, and TGF-β 
and involved in supporting immunological tolerance.48 Mouse 
models, where animals lack IL-10-producing B cells, proved 
that deficiency in B cell regulatory function results in chronic 
inflammation. However, the role of Breg cells in oral tolerance 
is not yet well established. Our group has shown that IL-10- se-
creting Breg (Br1) cells contribute to peripheral allergen toler-
ance. In bee venom allergic patients receiving AIT, the frequen-
cy of phosphilipase A2-specific, IL-10-producing B cells in-
creases. Additionally, IgG4, a non-inflammatory immunoglob-
ulin isotype that blocks IgE-mediated mast cells and basophils 
degranulation, was specifically produced by Br1 cells.49 The po-
tential mechanism through which IL-10-producing B cells may 
induce tolerance was investigated using IL-10-overexpressing B 
cells. These B cells could suppress DC maturation and T-effec-
tor cell proliferation, and secret less IgE. Furthermore, IL-10+B 
cells produced the anti-inflammatory IL-1 receptor antagonist 
and vascular endothelial growth factor, with reduced produc-
tion of pro-inflammatory cytokines.50 A recent study has sug-
gested that mesenteric IL-10-producing CD5+ Breg cells may 
play a role in the regulation of IgE-mediated anaphylaxis fol-
lowing challenge with cow’s milk allergens.51 In patients with 
non-IgE-mediated food allergy and AD, IL-10 producing B reg 
cells do not proliferate upon antigen stimulation, while these 
cells proliferate when obtained from tolerant volunteers. Simi-
lar responses have been shown for TGF-β producing B regula-
tory type 3 cells, suggesting that Breg cells may contribute to the 
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maintaince of tolerance in both IgE-mediated and non-IgE-
mediated food allergies.
A significant increase in the levels of IgG4 specific for food an-
tigens have been observed in many oral immunotherapy (OIT) 
studies. Despite an initial increase in food-specific IgE levels, 
the IgE levels usually decrease by the end of OIT and SLIT stud-
ies.52,53 An increase in IgG4 and a decrease in IgE might be due 
to the down-regulation of IL-4 production and up-regulation of 
IL-10 production because IL-10 induces heavy chain immuno-
globulin isotype switching to IgG4 and because IL-4 induces 
IgE. A possible role of food allergen-specific IgG4 in maintain-
ing desensitization and supporting tolerance was suggested in 
studies where peanut-specific IgG4 levels decreased after dis-
continuing maintenance dosing with allergen.54 As in OIT and 
SLIT, IgG4 levels in patients undergoing SCIT can be increased 
10-100 times. However, clinical improvement does not always 
correlate with IgG4 concentration in serum. 
 Additionally, mucosal IgA produced by B cells prevents up-
take of antigen across the epithelium and may protect against 
immunogenicity to food antigens.55
Role of microbiota in the induction of oral tolerance
Different cells that play a role in the induction and mainte-
nance of oral tolerance might be influenced by the presence of 
gut microbiota.56 It is well known that gut microbiota shape the 
intestinal immune system and impact barrier function.57 Mice 
that are bred under germ-free or sterile conditions do not fully 
develop tolerance mechanisms and similarly to mice treated 
with antibiotics or mice lacking  Toll-like receptors (TLRs), and 
are characterized by increased susceptibility to sensitization 
against food allergens.58 In addition, it has been shown that in 
the context of allergic inflammation, IgE production and baso-
phil development are suppressed in the presence of signals 
provided by commensal microbes.59 Furthermore, certain bac-
terial strains, such as Bifidobacterium longum 35624, Clostridia 
and Bacterioides fragilis can induce intestinal Treg cells that are 
capable of suppressing food allergy and colitis.60,61 Pattern-rec-
ognition receptor activation on DC seems to be an important 
mechanism by which intestinal microbes may promote Treg 
cell differentiation.62 On the other hand, intestinal microbes, 
such as segmented filamentous bacteria, can also promote the 
development of Th17 rather than Treg cells.
In murine experimental models of food allergy, it has been 
shown that mouse strains more susceptible to the development 
of food allergy possess a microbiome that differs from wild-type 
animals or non-susceptible but allergen-sensitized mice.58,63 In-
terestingly, more severe responses to food allergen challenge 
are observed in gnotobiotic mice reconstituted with microbes 
from allergic animals.64 In contrast, when gnotobiotic mice are 
colonized with microbiota from non-allergic children, these 
mice can be protected against allergen sensitization to milk al-
lergens.65 These results suggest that the microbiota may play 
both protective and detrimental roles in the development of 
food allergy.
One of the possible mechanisms to explain this phenomenon 
is that the microbiota normally instructs Treg cells to suppress 
Th2-derived responses. In the absence of these instructions, 
Treg cells change their phenotype to one which does not sup-
press food allergy but can actually participate in its develop-
ment.66 Support for this hypothesis comes from experiments 
where Treg cells from food allergy in susceptible, but not from 
resistant mice, had a mixed Treg-Th2 phenotype as they ex-
pressed the transcription factor GATA-3 and produced the cyto-
kine IL-4. In addition, deletion of Th2- cytokine genes specifical-
ly from Foxp3+ T cells prevents the development of food aller-
gy.66 Finally, another study has demonstrated that in the ab-
sence of an intestinal microbiota, Treg cells do not express 
RORγt, which favors the accumulation of GATA3+ Treg cells as 
well as Th2 cells.67
In addition to direct contact with microbial structures, the in-
testinal microbiome is metabolically active, and microbial me-
tabolites have been shown to exert significant effects on host 
immune signaling networks.68 Short-chain fatty acids (SCFA) 
are produced via microbiome fermentation of dietary fibers, 
and SCFA can promote DC cell regulatory activity, resulting in 
induction of Treg cells and IL-10-secreting T cells.69 In addition 
to SCFA, the microbiome secretes a wide range of other biolog-
ically important metabolites. For example, histamine is secret-
ed by gut microbes, and mucosal histamine levels are increased 
in patients with irritable bowel syndrome and inflammatory 
bowel disease.70 Histamine modifies chemokine and cytokine 
secretion by DC via the G protein-coupled receptor histamine 
receptor 2, while microbes secreting histamine exert immuno-
regulatory effects in mouse models.71 The interactions between 
microbiome and dietary factors, which influence oral toler-
ance, is currently an exciting area of study, particularly in food 
allergy.  
Tonsils as a possible place of tolerance induction
The palatine tonsils (PTs) are part of the mucosa-associated 
lymphoid tissue (MALT) in the human pharynx, which is called 
“Waldeyer’s ring.” Besides palatine tonsils, Waldeyer’s ring con-
sists of the nasopharyngeal tonsil (adenoid attached to the roof 
of the pharynx), paired tubal tonsils (at the openings of the Eu-
stachian tubes), and lingual tonsil (at the back of the tongue). 
PTs are easily accessible and the best studied among all the ton-
sils. PTs are positioned at the entry site of both the respiratory 
and gastrointestinal tracks, where foreign antigens and sub-
stances from food and air come into contact with the mucosal 
tissues, just before they are exposed to digestive enzymes and 
acidic gastric secretions. This is the strategic region where the 
immune response to diverse antigens that enter the body 
through the mouth and nose are initiated. Adenoids as well as 
PT can be removed; however, fully functional lingual and pha-
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rangeal tonsils probably take over their role. The characteristic 
feature of PT is the formation of deep tubular crypts that extend 
the external surface of the tonsil up to 300 cm2. Long-term con-
tact with antigens and direct stimulation of immune cells with 
food and air-borne allergens are possible due to this highly cryp-
tic surface. The outer surface of the PT is covered with stratified 
squamous non-keratinized epithelium. However, the crypt epi-
thelium is called “lymphoepithelium” as it is infiltrated with 
many of the non-epithelial cells, mainly lymphocytes. In the re-
ticulated epithelium, cells which functionally match intestinal 
M-cells are found. As they possess remarkable potential to tran-
scytose a broad range of particles and soluble material without 
their degradation, they translocate antigens to subepithelial 
lymphoid tissue. Immune cells, mainly lymphocytes, are found 
in all compartments of the tonsils, including the lymphoepithe-
lium, the inter-follicular regions, and the follicles. Among the in-
tra-epithelial lymphocytes, 50% are B cells with a smaller num-
ber of T cells, mostly CD4+ rather than CD8+ T cells. Similarly, 
secondary lymphoid follicles are mainly populated by B cells, 
where they undergo intense maturation and dynamic differenti-
ation. In addition to B cells, follicular T cells and follicular DC 
are found in the germinal center. Interestingly, McClory et al.72 
identified 5 tonsillar T cell developmental intermediates and 
proved that each of them resembles its thymic counterpart. With 
this work, it has been suggested that a full spectrum of T cell de-
velopment stages may take place in human tonsils.72 Tonsils 
have also been shown to be the potential first-line organ in-
volved in tolerance via the generation of allergen specific Foxp3+ 
T regulatory cells. It has been shown that there is a higher num-
ber of Bet v 1-specific CD4+Foxp3+ Treg cells in PT as compared 
to peripheral blood.73 Not only does tolerance induction occur 
in tonsils, but also allergen-specific T cell tolerance can be dis-
rupted in the tonsil upon stimulation with TLR4, TLR8, and pro-
inflammatory cytokines.74 From an immunological point of 
view, PT are a very interesting organ, but not yet fully investigat-
ed. It may be possible to develop novel immunotherapy proto-
cols that target these organs as a potential treatment of food al-
lergy. 
CONCLUSION
Dynamic interactions between host immune cells, microbi-
ome, dietary factors, and food allergens determine whether al-
lergy or tolerance develops. Despite a growing knowledge 
about food allergies, immune responses to food allergens di-
verge from default Treg cell- mediated suppressive responses 
to Th2-mediated, IgE-induced responses, still needs to be in-
vestigated. Oral tolerance is an active regulatory immune re-
sponse, and mechanisms inducing oral tolerance are summa-
rized here that it is mediated by allergen-specific Treg cells gen-
erated by mucosal DC. Intestinal mucins and cytokines coming 
from epithelial cells and innate lymphoid cells contribute to 
tolerance by modifying the phenotype of gastrointestinal DC. 
In addition, mucosal epithelial barrier regulation may play an 
important role.75 Oral tolerance by early dietary introduction 
can prevent peanut allergy in infants at high risk of peanut al-
lergy. As for humoral mechanisms, generation of allergen-spe-
cific IgG4 is especially associated with the development of tol-
erance to foods in humans. Clinical tolerance induced by im-
munotherapy is associated with changes in basophils, IgG4, al-
lergen-specific Th2 cells, and allergen-specific cells with regula-
tory markers.76,77 A more complete understanding of mecha-
nisms underlying the induction of oral tolerance with immuno-
therapy or natural tolerance to food allergens in healthy indi-
viduals will help develop better treatment options for patients 
suffering from food allergies. 
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